CCR2 and metabolic dysfunction-associated steatohepatitis: Cenicriviroc is a dual CCR2/CCR5 antagonist that has been investigated extensively in preclinical models of NASH and shown to diminish liver macrophage infiltration, inflammation, and fibrosis (Lefebvre et al., 2016; Krenkel et al., 2018), which is consistent with the effect of deleting CCR2 (Miura et al., 2012).